DELRICHT RESEARCH

CASE STUDY

3 Major Start-Up Milestones Achieved in an HS Trial

First Site Initiation Visit (SIV) · First Site Activation (FSA) · First Patient In (FPI)

Our Objectives

DelRicht Research was selected as a participating site network for a Hidradenitis Suppurativa study targeting participants aged 18-70 with at least a one-year history of HS, active painful lesions, and an overall severity score of Hurley Stage II or III.

- **Study Enrollment Goal:** 30 patients across 6 sites
- **DelRicht's Enrollment Goal:** 15 patients across 3 sites
- **Patient Population:** Adults 18-70 years old
- **Enrollment Period:** March 2026 - May 2026 (2 months)

Activation to Screening Timeline

ACTIVATION — **2 days** Avg. across 3 sites — FPFV

The Study

Client: Large Biopharma

Trial: U.S. Based Hidradenitis Suppurativa (HS) Chronic Pain Trial

Participating PIs

Dr. Christie Matter | Prosper, TX

Dr. Ira Thorla | Baton Rouge, LA

Dr. Stephanie Smith-Phillips | Mt Pleasant, SC

Key Trial Challenges & Solutions

CHALLENGES

eDairy Compliance:

The need for **multiple daily eDiary entries** and **smart device troubleshooting,** especially among older adults, significantly increased patient cognitive burden, while **daily charging requirements** for the wearable device heightened the risk of **missed logs and incomplete data.**

HOW DELRICHT ADDRESSED

Compliance Eduction & Monitoring:

To reduce technical inquiries and ensure data quality, we paired **proactive, patient-centered education** on app configuration, connectivity, and **mock eDiary logs** with daily oversight, **automated reminders, 24/7 support, and dedicated coordinator** follow-up for missed entries.

Our Results

DelRicht's 3 participating sites **enrolled 23 patients, achieving 153.2% of the enrollment goal,** averaged a **2-day activation to screening timeline,** and maintained a **95.6% retention rate.** In addition, Dr. Smith-Phillips was recognized for **First Site Initiation Visit, First Site Activation, and First Patient In studywide.** DelRicht's rapid site activation, coordinated execution, and patient retention reflects our network's ability to deliver high-impact results in complex protocols.

2 day Avg Activation to Screening

153.2% of the Expected Enrollment Goal

95.6% Retention Rate